

Giulio Cavalli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1786351/giulio-cavalli-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

3,585
citations

30
h-index

59
g-index

132
ext. papers

4,763
ext. citations

5.9
avg, IF

5.94
L-index

#	Paper	IF	Citations
112	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2020, 2, e325-e331	14.2	612
111	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-92	2.2	371
110	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49	3.9	270
109	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285	2.4	164
108	Suppression of inflammation and acquired immunity by IL-37. <i>Immunological Reviews</i> , 2018, 281, 179-190	1.3	140
107	Anakinra Therapy for Non-cancer Inflammatory Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 1157	5.6	137
106	The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1691-5	2.4	129
105	Erdheim-Chester disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 223-9	3.9	99
104	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1752-1760	50.5	93
103	Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. <i>Rheumatology</i> , 2015, 54, 2134-44	3.9	76
102	BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1596-602	2.4	75
101	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e253-e261	14.2	75
100	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369	5.6	68
99	MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1363-8	11.5	65
98	Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2313-2318	11.5	60
97	Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. <i>Rheumatology</i> , 2016, 55, 2220-2229	3.9	56
96	Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 48-54	5.3	55

95	Efficacy and safety of biological agents in adult-onset Still's disease. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 309-14	1.9	51
94	Treating Life-Threatening Myocarditis by Blocking Interleukin-1. <i>Critical Care Medicine</i> , 2016 , 44, e751-4	1.4	51
93	Interleukin 1 α comprehensive review on the role of IL-1 α in the pathogenesis and treatment of autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2021 , 20, 102763	13.6	44
92	Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. <i>Frontiers in Immunology</i> , 2017 , 8, 131	8.4	42
91	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. <i>European Journal of Internal Medicine</i> , 2021 , 86, 34-40	3.9	39
90	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology, The</i> , 2021 , 3, e690-e697	14.2	38
89	Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. <i>Autoimmunity Reviews</i> , 2015 , 14, 352-7	13.6	35
88	Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease. <i>Frontiers in Immunology</i> , 2014 , 5, 281	8.4	35
87	Treating pulmonary silicosis by blocking interleukin 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 596-8	10.2	34
86	Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1357-62	11.5	33
85	FRI0506 EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILL'S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 851.1-852	2.4	33
84	Autophagy and Protein Secretion. <i>Journal of Molecular Biology</i> , 2020 , 432, 2525-2545	6.5	32
83	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2018 , 9, 1233	8.4	32
82	Myocarditis: An Interleukin-1-Mediated Disease?. <i>Frontiers in Immunology</i> , 2018 , 9, 1335	8.4	30
81	Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. <i>Journal of Biological Chemistry</i> , 2018 , 293, 14224-14236	5.4	29
80	Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. <i>Annals of Internal Medicine</i> , 2018 , 169, 819-820	8	26
79	Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. <i>Arthritis Research and Therapy</i> , 2019 , 21, 54	5.7	25
78	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 536-544	2.4	25

77	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , 2018 , 57, e11-e12	3.9	24
76	Tocilizumab in patients with multisystem Erdheim-Chester disease. <i>Oncolmmunology</i> , 2017 , 6, e1318237.2		23
75	The right place for IL-1 inhibition in COVID-19. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 223-224	35.1	21
74	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021 , 133, 104071	3.7	21
73	The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. <i>Cell Reports</i> , 2021 , 35, 108955	10.6	20
72	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019 , 10, 296	5.6	17
71	Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , 2020 , 59, 171-175	3.9	17
70	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017 , 239, 33	3.2	15
69	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020 , 11, 598308	5.6	14
68	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2018 , 7, e1440929	7.2	13
67	Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2019 , 48, 482-490	1.9	12
66	Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. <i>International Journal of Cardiology</i> , 2018 , 252, 21-23	3.2	12
65	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. <i>Journal of Neurology</i> , 2018 , 265, 273-284	5.5	12
64	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2016 , 5, e1181244	7.2	10
63	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, e143-e146	1.1	10
62	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 509-514	5.3	9
61	Diagnosing Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, e19	2.4	9
60	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2019 ,	2.4	9

59	Current treatment options and safety considerations when treating adult-onset Still's disease. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1549-1558	4.1	8
58	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021 , 12, 653950	8.4	7
57	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020 , 7, 42	4.9	6
56	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1313-1322	5.1	6
55	Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera: A Case Report. <i>Medicine (United States)</i> , 2016 , 95, e3697	1.8	6
54	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1-6	5.3	6
53	Erdheim-Chester disease: An in vivo human model of M ϕ activation at the crossroad between chronic inflammation and cancer. <i>Journal of Leukocyte Biology</i> , 2020 , 108, 591-599	6.5	5
52	2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	5
51	Advances in potential targeted therapies for Erdheim-Chester disease. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 1-8	1.1	4
50	Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case. <i>Modern Rheumatology</i> , 2016 , 26, 276-7	3.3	4
49	THU0209 Efficacy of anti-TNF therapy in 15 patients with refractory takayasu's arteritis: Long term unicentric follow-up. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 226.1-226	2.4	4
48	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use. <i>Journal of Clinical Rheumatology</i> , 2019 ,	1.1	4
47	Maladaptive autophagy in the pathogenesis of autoimmune epithelitis in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	3
46	Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. <i>Nature Communications</i> , 2021 , 12, 4559	17.4	3
45	3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 862-864	2.4	3
44	Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.. <i>RMD Open</i> ,	5.9	3
43	Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. <i>RMD Open</i> , 2022 , 8, e002167	5.9	3
42	Orthopnea with platydeoxia secondary to prominent Eustachian valve. <i>Intensive Care Medicine</i> , 2015 , 41, 918-9	14.5	2

41	Letter by Campochiaro et al Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". <i>Circulation</i> , 2018 , 137, 2421-2422	16.7	2
40	Charcot's arthropathy of the spine. <i>Arthritis and Rheumatism</i> , 2013 , 65, 342		2
39	A bitter effect: thrombocytopenia induced by a quinidine-containing beverage. <i>American Journal of Medicine</i> , 2014 , 127, e1-2	2.4	2
38	Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it?. <i>European Review for Medical and Pharmacological Sciences</i> , 2018 , 22, 2189-2190	2.9	2
37	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021 , 138, 1554-1569	2.2	2
36	Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 2, e156-e157	1.9	2
35	AB0621 GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS 2019 ,		2
34	A Novel Histiocytosis With Synovial and Skin Involvement. <i>Annals of Internal Medicine</i> , 2021 , 174, 273-274		2
33	Publications Are Not the Finish Line: Focusing on Societal Rather Than Publication Impact. <i>Frontiers in Medicine</i> , 2018 , 5, 314	4.9	2
32	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, e140-e141	1.1	1
31	An enlightening scan. <i>European Journal of Internal Medicine</i> , 2015 , 26, 68-9	3.9	1
30	Charcot's arthropathy of the hip. <i>Journal of Rheumatology</i> , 2013 , 40, 1770	4.1	1
29	Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. <i>Genome Medicine</i> , 2021 , 13, 94	14.4	1
28	Successful use of cyclosporin A and interleukin-1 blockers combination in VEXAS syndrome: a single-centre case series.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	1
27	Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.. <i>RMD Open</i> , 2022 , 8,	5.9	1
26	Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2014 , 166, 470	4.5	0
25	Myocarditis as a manifestation of Erdheim-Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 1-3	1.9	0
24	The course of action for effective anti-cytokine treatment in COVID-19. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1353-1354	35.1	0

23	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2020 , 47, 1780-1784	4.1	○
22	POS1341 TOCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 953.1-953.4	2.4	○
21	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab015	1.1	○
20	Canakinumab injection for the treatment of active Still's disease, including adult-onset Still's disease. <i>Expert Opinion on Orphan Drugs</i> , 2021 , 9, 77-86	1.1	○
19	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). <i>Frontiers in Medicine</i> , 2021 , 8, 723506	4.9	○
18	THU0372 The Role of Echocardiography and Cardiac MRI in Erdheim-Chester Disease. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 311.1-311	2.4	
17	AB0742 Pure peripheral giant cell arteritis: A systematic literature review of a poorly characterized clinical entity. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 681.2-681	2.4	
16	AB0746 Juvenile temporal arteritis: Report of a case and review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 681.6-681	2.4	
15	THU0386 Efficacy of long-term treatment with biologic agents in refractory adult onset still's disease: A single centre experience on 16 patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 286.1-286.4	2.4	
14	FRI0486 Cardiac cine mri in erdheim-chester disease: data from a large italian cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A539.2-A539	2.4	
13	THU0373 Clinical presentation of erdheim-chester disease: Data from a cohort of 10 patients and review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 281.3-282	2.4	
12	FRI0484 SAFETY PROFILE, CLINICAL AND RADIOLOGICAL EFFICACY OF ANAKINRA, TARGETED AND COMBINED TREATMENT IN ERDHEIM-CHESTER DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 839.1-840	2.4	
11	SAT0519 DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1215-1216	2.4	
10	Autophagy in the regulation of protein secretion in immune cells 2020 , 141-173		
9	Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. <i>European Journal of Internal Medicine</i> , 2020 , 82, 23-24	3.9	
8	The choice of early treatment and the impact of future relapses in adult onset Still's disease. <i>Rheumatology</i> , 2021 , 60, 2500-2501	3.9	
7	POS1347 IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILL'S DISEASE PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 955.3-956	2.4	
6	POS0370 TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 115-115	2.4	

- 5 POS1336 RETROPERITONEAL FIBROSIS IN ERDHEIM-CHESTER DISEASE HAS UNIQUE PRESENTING AND PROGNOSTIC FEATURES: A SINGLE CENTRE RETROSPECTIVE COMPARATIVE COHORT STUDY. *Annals of the Rheumatic Diseases*, **2021**, 80, 950-951 2.4
- 4 FRI0001 Treating Experimental Arthritis with The Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation. *Annals of the Rheumatic Diseases*, **2016**, 75, 426.1-426 2.4
- 3 Anakinra in COVID-19-How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarro-Millán et al. *Arthritis and Rheumatology*, **2021**, 73, 549 9.5
- 2 In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome. *Rheumatology*, **2021**, 60, 5493-5494 3.9
- 1 Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. *Clinical and Experimental Rheumatology*, **2022**, 2.2